WO2006125180B1 - Derives de piperazine: utilisation comme agents therapeutiques - Google Patents

Derives de piperazine: utilisation comme agents therapeutiques

Info

Publication number
WO2006125180B1
WO2006125180B1 PCT/US2006/019562 US2006019562W WO2006125180B1 WO 2006125180 B1 WO2006125180 B1 WO 2006125180B1 US 2006019562 W US2006019562 W US 2006019562W WO 2006125180 B1 WO2006125180 B1 WO 2006125180B1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
group
hydrogen
independently selected
cycloalkylalkyl
Prior art date
Application number
PCT/US2006/019562
Other languages
English (en)
Other versions
WO2006125180A1 (fr
Inventor
Jianmin Fu
Shifeng Liu
Original Assignee
Xenon Pharmaceuticals Inc
Jianmin Fu
Shifeng Liu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenon Pharmaceuticals Inc, Jianmin Fu, Shifeng Liu filed Critical Xenon Pharmaceuticals Inc
Publication of WO2006125180A1 publication Critical patent/WO2006125180A1/fr
Publication of WO2006125180B1 publication Critical patent/WO2006125180B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes de traitement d'une maladie ou d'un état pathologique véhiculé par la stéaryle-CoA désaturase (SCD) chez un mammifère, de préférence un humain. Les méthodes de l'invention consistent à administrer au mammifère un composé de formule (I), dans laquelle p, G, J, K, L, M, V, R2, R3, R5, R6 et R6a sont tels que définis dans la description. Par ailleurs, l'invention concerne des compositions pharmaceutiques qui renferment les composés de formule (I).
PCT/US2006/019562 2005-05-19 2006-05-19 Derives de piperazine: utilisation comme agents therapeutiques WO2006125180A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68292605P 2005-05-19 2005-05-19
US60/682,926 2005-05-19

Publications (2)

Publication Number Publication Date
WO2006125180A1 WO2006125180A1 (fr) 2006-11-23
WO2006125180B1 true WO2006125180B1 (fr) 2007-02-15

Family

ID=36939998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/019562 WO2006125180A1 (fr) 2005-05-19 2006-05-19 Derives de piperazine: utilisation comme agents therapeutiques

Country Status (1)

Country Link
WO (1) WO2006125180A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101506203B (zh) 2006-08-24 2013-10-16 诺瓦提斯公司 治疗代谢病、心血管病和其他病症的作为硬脂酰辅酶a脱饱和酶(scd)抑制剂的2-(吡嗪-2-基)-噻唑和2-(1h-吡唑-3-基)-噻唑衍生物及相关化合物
US8575167B2 (en) 2007-02-06 2013-11-05 Takeda Pharmaceutical Company Limited Spiro compounds having stearoyl-CoA desaturase action
JP2010518104A (ja) * 2007-02-09 2010-05-27 アストラゼネカ・アクチエボラーグ アザ−イソインドロンおよび代謝型グルタミン酸レセプター増強剤−６１３としてのそれらの使用
PA8782701A1 (es) * 2007-06-07 2009-01-23 Janssen Pharmaceutica Nv Antagonistas del receptor de urotensina ii
US7842696B2 (en) 2007-06-21 2010-11-30 Forest Laboratories Holdings Limited Piperazine derivatives as inhibitors of stearoyl-CoA desaturase
JP2011516494A (ja) * 2008-04-07 2011-05-26 ギリアード サイエンシーズ， インコーポレイテッド ステアロイル−ＣｏＡデサチュラーゼの阻害剤として使用するための２Ｈ−ベンゾ［ｂ］［１，４］オキサジン−３（４Ｈ）−オン誘導体
EP2350029A1 (fr) * 2008-10-15 2011-08-03 Gilead Sciences, Inc. Dérivés de 3-hydroquinazoline-4-one utilisés comme inhibiteurs de stéaryl-acp désaturase
CA2750564A1 (fr) 2009-02-17 2010-08-26 Merck Canada Inc. Nouveaux composes spiro utiles comme inhibiteurs de la stearoyl-coenzyme a delta-9 desaturase
US8383643B2 (en) 2009-07-28 2013-02-26 Merck Canada Inc. Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
WO2011030312A1 (fr) 2009-09-10 2011-03-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux inhibiteurs de stearoyl-coa-desaturase-1 et leurs utilisations
EA201270778A1 (ru) 2010-05-06 2013-04-30 Бристол-Майерс Сквибб Компани Бициклические гетероарильные аналоги в качестве модуляторов рецептора gpr119
WO2013056015A1 (fr) 2011-10-14 2013-04-18 Incyte Corporation Dérivés d'isoindolinone et de pyrrolopyridinone en tant qu'inhibiteurs d'akt
MX2014004426A (es) 2011-10-15 2014-07-09 Genentech Inc Metodos de uso de antagonistas de scd1.
BR112014029365A2 (pt) 2012-05-22 2017-06-27 Hoffmann La Roche inibidores seletivos de células indiferenciadas
WO2017107089A1 (fr) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. Modulateurs allostériques 3-(1h-pyrazol-4-yl)pyridine du récepteur muscarinique m4 de l'acétylcholine
US10329289B2 (en) 2015-12-23 2019-06-25 Merck Sharp & Dohme Corp. 6,7-dihydro-5H-pyrrolo[3,4-B]pyridin-5-one allosteric modulators of the M4 muscarinic acetylcholine receptor
WO2018112840A1 (fr) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Modulateurs allostériques d'éther d'hétéroarylpipéridine 6, 5-fusionnés du récepteur muscarinique d'acétylcholine m4
WO2018112842A1 (fr) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Modulateurs allostériques d'éther hétéroarylpipéridine 6,6-fusionné du récepteur muscarinique de l'acétylcholine m4
WO2018112843A1 (fr) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Modulateurs allostériques d'éther hétéroarylpipéridine du récepteur muscarinique de l'acétylcholine m4
WO2019000237A1 (fr) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. Modulateurs allostériques de 3-(1h-pyrazol-4-yl)pyridine du récepteur muscarinique m4 de l'acétylcholine
WO2019000238A1 (fr) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. Modulateurs allostériques de 5-(pyridin-3-yl)oxazole du récepteur muscarinique m4 de l'acétylcholine
WO2019000236A1 (fr) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. Modulateurs allostériques de 3-(1h-pyrazol-4-yl)pyridine du récepteur muscarinique m4 de l'acétylcholine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6165873A (ja) * 1984-09-07 1986-04-04 Mitsui Petrochem Ind Ltd ２−ピペラジノピリミジン誘導体
JPH0635460B2 (ja) * 1985-04-22 1994-05-11 三井石油化学工業株式会社 ２−ピペラジノピリミジン誘導体
US4959368A (en) * 1986-02-24 1990-09-25 Mitsui Petrochemical Industries Ltd. Therapeutic agent for neurological diseases
US5304555A (en) * 1987-08-26 1994-04-19 Mitsui Petrochemical Industries, Ltd. Pyrimidines and pharmaceutically acceptable salts thereof useful in treatment of neurological disorders
US6417362B1 (en) * 1997-05-30 2002-07-09 Meiji Seika Kaisha, Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
KR20020005662A (ko) * 1999-04-09 2002-01-17 기따자또 이찌로 질소함유 복소환화합물 및 벤즈아미드화합물 및 그 것을함유해서 되는 의약
ATE556056T1 (de) * 2003-07-29 2012-05-15 Xenon Pharmaceuticals Inc Pyridylderivate und deren verwendung als therapeutische mittel
CN101712653A (zh) * 2003-07-30 2010-05-26 泽农医药公司 哒嗪衍生物和它们作为治疗剂的用途
JP4808616B2 (ja) * 2003-07-30 2011-11-02 ゼノン・ファーマシューティカルズ・インコーポレイテッド ピリダジン誘導体および治療剤としてのその用途
BRPI0412348A (pt) * 2003-07-30 2006-09-05 Xenon Pharmaceuticals Inc derivados de piperazina e seu uso como agentes terapêuticos
AU2004261267B9 (en) * 2003-07-30 2009-04-09 Xenon Pharmaceuticals Inc. Pyridyl derivatives and their use as therapeutic agents
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators

Also Published As

Publication number Publication date
WO2006125180A1 (fr) 2006-11-23

Similar Documents

Publication Publication Date Title
WO2006125180B1 (fr) Derives de piperazine: utilisation comme agents therapeutiques
AU2012351747B2 (en) Prodrugs of secondary amine compounds
JP2008513498A5 (fr)
US20100179114A1 (en) S-Isomer of 2- piperidine and Other Dermal Anesthetic Agents
RU2006105717A (ru) Производные пиперазина и их применение в качестве терапевтических агентов
JP2008513516A5 (fr)
EA005975B1 (ru) Соединения пиперазинилпиразинов в качестве антагонистов серотонин 5-ht2 рецептора
CA2597069A1 (fr) Derives de pyridazine et leur utilisation en tant qu'agents therapeutiques
WO2018188641A1 (fr) Composition pharmaceutique contenant un agoniste du mor et un agoniste du kor, et ses utilisations
WO2009009501A3 (fr) Antagonistes de récepteur 1 d'hormone de concentration de mélanine non basique et procédés
TW200607807A (en) Macrocyclic beta-secretase inhibitors
MX2007009592A (es) Terapia de combinacion.
JP2008513496A5 (fr)
WO2007050726A3 (fr) Antagonistes du recepteur 1 de l'hormone de concentration de la melanine non basiques
WO2006088193A1 (fr) Agent anti-tumoral
RU2006105716A (ru) Производные пиридазина и их применение в качестве терапевтических средств
RU2009136592A (ru) Терапевтические агенты
RU2007128080A (ru) Производные пирролидиния в качестве мускариновых рецепторов мз
CA2521621A1 (fr) Composes destines au traitement de troubles metaboliques
JP2004507527A5 (fr)
WO2006118307A1 (fr) Agent therapeutique contre la douleur
WO2009096701A3 (fr) Nouveaux composés, isomère ou sels pharmaceutiquement acceptables de ces derniers, utilisés comme antagonistes du récepteur vanilloïde, et compositions pharmaceutiques les contenant
UA81640C2 (ru) Противомикобактериальные соединения, способ их получения, фармацевтическая композиция на их основе
CZ260694A3 (en) The use of bisphenylalkyl piperazines
JP2004526721A5 (fr)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

NENP Non-entry into the national phase in:

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06770726

Country of ref document: EP

Kind code of ref document: A1